How to Discontinue Nadolol
Nadolol should be gradually tapered over 1-2 weeks rather than stopped abruptly, particularly in patients with ischemic heart disease, to prevent potentially life-threatening withdrawal complications including exacerbation of angina, myocardial infarction, and rebound hypertension. 1, 2, 1, 3
Why Gradual Tapering is Critical
The 2017 ACC/AHA Hypertension Guidelines explicitly state to "avoid abrupt cessation" of nadolol 1, 2, 4, 1, 5, 6. The FDA drug label for nadolol provides the most authoritative guidance, warning that abrupt discontinuation can cause:
- Exacerbation of angina pectoris
- Myocardial infarction
- Sudden death (in patients with coronary artery disease)
- Hypersensitivity to catecholamines (beta-blocker withdrawal syndrome) 3
This occurs because chronic beta-blockade leads to upregulation of beta-receptors, making patients hypersensitive to endogenous catecholamines when the drug is suddenly stopped 7, 8.
Specific Tapering Protocol
Reduce the dose gradually over 1-2 weeks while carefully monitoring the patient 3. For example:
- If on nadolol 80 mg daily, reduce to 40 mg daily for 1 week, then 20 mg daily for several days before stopping
- Higher doses or longer treatment duration may require more extended tapers
High-Risk Patients Requiring Extra Caution
Patients with ischemic heart disease are at highest risk and require the most careful tapering 3. The FDA label specifically warns that even patients treated only for hypertension may have unrecognized coronary artery disease, so prudent practice dictates gradual discontinuation in all patients 3.
Additional high-risk groups:
- Patients with heart failure: Beta-blocker discontinuation significantly increases in-hospital mortality (RR 3.72), short-term mortality (RR 1.61), and rehospitalization rates (RR 1.59) 9
- Post-myocardial infarction patients: Discontinuation beyond 1 year post-MI increases risk of death or ACS readmission (HR 1.17) 10
- Patients with thyrotoxicosis: Abrupt withdrawal may precipitate thyroid storm 3
Monitoring During Discontinuation
Watch closely for signs of withdrawal syndrome:
- Worsening angina or chest pain
- Elevated blood pressure (may exceed pre-treatment levels)
- Tachycardia
- Tremor, sweating, agitation, headache (sympathetic overactivity) 7, 8
- Palpitations
If angina markedly worsens or acute coronary insufficiency develops, reinstitute nadolol immediately and implement other measures for unstable angina 3.
Special Considerations
Patients should be explicitly warned not to interrupt or discontinue therapy without physician guidance 3. One case report documented unusually prolonged and severe sympathetic overactivity when nadolol was abruptly stopped 7.
In acute decompensated heart failure: Beta-blockers should generally be continued if the clinical picture allows, as discontinuation increases mortality and rehospitalization 9. Dose reduction may be needed in some cases, but complete withdrawal should be avoided unless the patient is in cardiogenic shock 11, 12.
Perioperative management: Chronically administered beta-blockers should not be routinely withdrawn prior to major surgery 3. Postoperative discontinuation is particularly dangerous—mortality was 50% in patients who stopped beta-blockers post-vascular surgery versus 1.5% in those who continued 13.
Common Pitfall to Avoid
Do not assume that nadolol's long half-life (14-24 hours, extended to 18-68 hours in renal disease) 14 makes gradual tapering unnecessary. The withdrawal syndrome is related to receptor upregulation, not simply drug washout, and nadolol has been documented to cause severe discontinuation syndromes despite its pharmacokinetic properties 7.